Literature DB >> 25910609

Pleomorphic leiomyosarcoma with a dedifferentiation-like appearance in the kidney: case report and literature review.

Shogo Tajima1, Michihiko Waki2, Masashi Fukuyama2.   

Abstract

Although primary leiomyosarcoma of the kidney is extremely rare, it is the most common sarcoma of the kidney. Leiomyosarcoma with a large pleomorphic component is designated as pleomorphic leiomyosarcoma. The pleomorphic component is usually similar to undifferentiated high-grade pleomorphic sarcoma, although it variably expresses smooth muscle markers on immunohistochemistry. In the few reported cases of pleomorphic leiomyosarcoma of the kidney, cases with the pleomorphic component showing distinct nodularity similar to dedifferentiated leiomyosarcoma have not been described, to the best of our knowledge. Herein, we present a case of a 49-year-old woman with pleomorphic leiomyosarcoma in the kidney showing distinct nodularity of smooth muscle marker-expressing pleomorphic cells within a background of classic leiomyosarcoma. Along with the classification as a pleomorphic leiomyosarcoma, suggesting aggressive clinical behavior, the renal origin itself might also be a predictor of poor prognosis, as shown in a previous study. This case also involved concomitant distant metastases, already present during the initial detection of the renal tumor.

Entities:  

Keywords:  Dedifferentiation; Kidney; Metastasis; Pleomorphic leiomyosarcoma; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 25910609     DOI: 10.1007/s00795-015-0103-6

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  13 in total

1.  Leiomyosarcoma of the renal pelvis.

Authors:  S M Moudouni; I En-Nia; N Rioux-Leclerq; F Guille; B Lobel
Journal:  Scand J Urol Nephrol       Date:  2001-10

2.  Cytokeratin expression in smooth muscle and smooth muscle tumours.

Authors:  D C Brown; J M Theaker; P M Banks; K C Gatter; D Y Mason
Journal:  Histopathology       Date:  1987-05       Impact factor: 5.087

3.  Pleomorphic leiomyosarcoma: clinicopathologic and immunohistochemical study with special emphasis on its distinction from ordinary leiomyosarcoma and malignant fibrous histiocytoma.

Authors:  Y Oda; K Miyajima; K Kawaguchi ; S Tamiya; Y Oshiro; Y Hachitanda; M Oya; Y Iwamoto; M Tsuneyoshi
Journal:  Am J Surg Pathol       Date:  2001-08       Impact factor: 6.394

4.  Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.

Authors:  M de Peralta-Venturina; H Moch; M Amin; P Tamboli; S Hailemariam; M Mihatsch; J Javidan; H Stricker; J Y Ro; M B Amin
Journal:  Am J Surg Pathol       Date:  2001-03       Impact factor: 6.394

5.  Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation.

Authors:  W H Henricks; Y C Chu; J R Goldblum; S W Weiss
Journal:  Am J Surg Pathol       Date:  1997-03       Impact factor: 6.394

6.  The comparative survival of renal leiomyosarcoma.

Authors:  Wayne S Kendal
Journal:  Can J Urol       Date:  2007-02       Impact factor: 1.344

7.  Smooth muscle cell phenotypic diversity between dissected and unaffected thoracic aortic media.

Authors:  J Zhang; L Wang; W Fu; C Wang; D Guo; J Jiang; Y Wang
Journal:  J Cardiovasc Surg (Torino)       Date:  2013-04-18       Impact factor: 1.888

8.  Primary leiomyosarcoma of the kidney: a clinicopathologic study of 27 cases.

Authors:  Jeremy S Miller; Ming Zhou; Fadi Brimo; Charles C Guo; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2010-02       Impact factor: 6.394

9.  Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma.

Authors:  C D Fletcher
Journal:  Am J Surg Pathol       Date:  1992-03       Impact factor: 6.394

10.  Embryonic form of smooth muscle myosin heavy chain (SMemb/MHC-B) in gastrointestinal stromal tumor and interstitial cells of Cajal.

Authors:  S Sakurai; T Fukasawa; J M Chong; A Tanaka; M Fukayama
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.